logo
How Prison Guards Used An Illegal Strike To Fight Reform

How Prison Guards Used An Illegal Strike To Fight Reform

Yahoo28-03-2025
A three-weeklong wildcat strike by thousands of New York state correctional officers across more than 40 prisons ended earlier this month, during which time 12 incarcerated people died, and many more struggled from weeks of being deprived of adequate food, medical care, time out of their cell, and access to their lawyers and loved ones.
Striking prison guards cited staffing shortages, mandatory overtime and dangerous working conditions as their reasons for walking off the job. But the strike was also the result of a years-long effort by correctional officers to overturn a state law limiting the use of solitary confinement in New York state prisons and jails. Passed in 2021 and implemented the following year, the Humane Alternatives to Long-Term Solitary Confinement Act (HALT), capped the number of consecutive days a person could be kept in solitary confinement to 15 days— after which point the United Nations considers it a form of torture. HALT also banned solitary for people with disabilities.
The bill was passed in recognition of overwhelming evidence of the harmful physical and mental health effects of solitary confinement. But shortly after it passed, the New York State Correctional Officers & Police Benevolent Association (NYSCOPBA), the union that represents prison guards, sued state officials in an effort to repeal HALT, claiming the reform bill violated their constitutional rights by putting them at risk of injury or death.
'The harm to life and limb of Correction Officers and Correction Sergeants that has been and will continue to occur constitutes irreparable harm and shocks the contemporary conscience,' they alleged in a complaint.
A judge dismissed the lawsuit in 2022 as 'speculative,' but the correctional officers union vowed to keep fighting to overturn the law. Starting in mid-February, approximately 15,000correctional officers at nearly every New York state prison walked off their jobs. The strike was unsanctioned by the union and violated a state ban on public employees striking. Still, the union succeeded in one of their long-held goals. Earlier this month, the strike ended with state officials agreeing to, among other provisions, suspending parts of HALT for 90 days and agreeing to form a committee to recommend changes to the law.
'The strike was clearly a frontal assault on HALT and its protections,' Antony Gemmell, a supervising attorney for the Prisoners' Rights Project at the Legal Aid Society, told HuffPost.
It was unlikely New York state lawmakers would repeal HALT, James Miller, NYSCOPBA's director of public relations said in an interview, 'so at least getting some temporary amendments to limit how it's implemented is a success.'
Throughout the strike, lawyers at the Legal Aid Society received hundreds of calls from their clients, describing a 'flood of human desperation,' Kayla Simpson, a staff attorney at Legal Aid's Prisoners' Rights Project said. 'It's hard to imagine as people who haven't been incarcerated what it's like to depend on people for your basic needs — and then to have those people walk away.'
'This is not an acceptable way to meet labor demands. People died, far more have suffered,' Simpson said. 'We wouldn't accept these conditions for animals.'
Simpson and her colleagues compiled some of the accounts shared by Legal Aid clients into a report released on Friday, which documents the human cost of the illegal strike. Legal Aid did not disclose the identities of those quoted in the report because of fears of retaliation, and HuffPost could not independently confirm their accounts.
Multiple people told Legal Aid that their facilities had shut down 'sick call,' leaving them unable to get medical care. One person incarcerated at Attica Correctional Facility told Legal Aid he was unable to get supplies to clean and dress chronic ulcers related to a blood clot in his leg, causing his leg to swell and the wound to produce foul-smelling pus. Another person at Attica, who has epilepsy, reported being ignored after reporting symptoms that typically lead to a seizure. A third person at Attica, who had open-heart surgery in 2020 and has atrial fibrillation, said their weekly medical visits stopped during the strike.
'I haven't gotten the medications I'm supposed to have in two weeks. I have one I can administer to myself, but I'm running out so I'm rationing it and it is not good. I don't know what I'm going to do,' a person incarcerated at Marcy Correctional Facility said. 'I also am supposed to have physical therapy to help me relearn to walk, but that's deemed 'non-essential' so it's canceled.'
An individual at Five Points Correctional Facility told Legal Aid they experienced seizures and COVID symptoms during the strike but still couldn't get medical care. 'They're playing with our lives in here,' the person said. 'The other day I must have been laying there for 20-30 minutes and no one saw me. I woke up in a lot of pain, and no one even realized anything was happening until I yelled out after the fact. When I told a nurse about it, she told me to yell louder next time.'
Nicole Whitaker, the deputy director of public information at New York's Department of Corrections and Community Supervision, said in an email, 'The Department remains focused on keeping everyone inside the correctional facilities safe and secure, as well as providing essential services including but not limited to meals, showers, telephones, commissary and delivery of packages, along with medical and mental health care, including medication.' Allegations of mistreatment have been referred to the Office of Special Investigations, she wrote.
'There were 12 incarcerated individual deaths during the strike, as compared to 13 deaths in the same period last year,' Whitaker wrote.
Even after the strike ended earlier this month,incarcerated people told Legal Aid attorneys that they continued to experience neglectful conditions and hostility from returning officers. Several said they feared being injured or even killed by guards, citing the murder of Robert Brooks, who was fatally beaten by correctional officers in December at the prison in Marcy.
One person incarcerated at Mid-State Correctional Facility told Legal Aid he overheard a correction officer who had recently returned to work say he wanted to 'kill all the inmates and that we all deserved to die because of our criminal history,' according to the report.
'Whatever the COs are going through, they're taking their anger out on us and bringing it back to us,' another person, who is incarcerated at Coxsackle Correctional Facility, told Legal Aid. 'I understand that most of us made wrong turns in life, but I want to go home. I don't want to get killed in here. I have kids and family to get home to, and a lot of us are starting to feel like our lives are in real danger here.'
Asked about these fears, Whitaker wrote, 'While the strike has ended, we are not out of the crisis. Each facility is developing a gradual re-opening plan. In terms of the allegations, those that have been reported by an incarcerated individual claiming mistreatment have been referred to OSI for further investigation.'
Although DOCCS tracks assaults by incarcerated people against staff, it does not publicly share statistics about staff assaults against the incarcerated. DOCCS data does show an increase in assaults on staff after HALT went into effect, although the overwhelming majority are described as resulting in 'no injury.' The department considers actions by prisoners like throwing a 'small object' at a staffer to be a form of assault.
Last year, the Legal Aid Society, Disability Rights Advocates, and Winston & Strawn LLP filed a class action lawsuit against DOCCS, accusing the department of violating HALT by holding people with disabilities in solitary confinement. DOCCS declined to comment on the pending litigation.
'DOCCS has never complied with HALT from the beginning,' said Gemmell, one of the attorneys representing the plaintiffs in the suit. 'A huge part of what HALT intended to do is take people who would otherwise be placed in extended segregated confinement and offer them rehabilitation and therapy. That is not happening.'
'You can't look at HALT and say it's a failure when the reality is DOCCS has never given HALT a real chance to work,' said Gemmell.
Prisons Said It Was COVID Isolation. The Incarcerated Describe Torture.
Bodycam Video Shows New York Correctional Officers Pummeling Handcuffed Man In Fatal Beating
Over 122K People Are Experiencing Solitary Confinement On Any Day: Report
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Delays in anti-drunken driving auto tech frustrate Illinois mom who lost son in crash
Delays in anti-drunken driving auto tech frustrate Illinois mom who lost son in crash

CBS News

time29-07-2025

  • CBS News

Delays in anti-drunken driving auto tech frustrate Illinois mom who lost son in crash

The mother of a McHenry, Illinois man who was killed by a drunken driver in 2018 is pushing for a technology in new cars that she said would have saved her son's life — and she is frustrated by delays in its implementation. Sheila Lockwood lost her 23-year-old son, Austin, to a drunken driver on June 10, 2018. Every single day since, Lockwood has been teaming up with stakeholders trying to make it harder for drunken drivers to get behind the wheel. "We know that there's technology that could stop this from happening," said Lockwood. In 2021, Lockwood was instrumental in helping get the HALT Act signed into law. The acronym stands for "Honoring Abbas Family Legacy to Terminate Drunk Driving," and is named for Issam and Rima Abbas of the Detroit area and their three children — Ali, 13; Isabelle, 12; and Giselle, 7 — who were struck and killed by a wrong-way drunken driver on I-75 near Lexington, Kentucky, while returning from a Florida vacation in January 2019. The law requires a new federal regulation for anti-drunken driving technology to be installed in new cars. The technology can passively detect a drunk driver by the air he or she breathes out. It measures the ratio of carbon dioxide and alcohol to determine what a would-be driver's blood alcohol must be. Mothers Against Drunk Driving was joined by members of the auto insurance industry and the alcohol industry in advocating for the tech in new vehicles. "Anheuser-Busch is a huge supporter," said Lockwood. The target rollout year for the tech was 2026. But nearly four years later, the finish line has been pushed back — in part thanks to pushback from some lawmakers trying to repeal the requirement using another piece of legislation, the No Kill Switches in Cars Act. One lawmaker, U.S. Rep. Scott Perry (R-Pennsylvania) claimed the anti-DUI technology can be used to "restrict your travel or to track you without a warrant." "There's been a lot of false information out there," Lockwood said. "Nobody has the right to drive impaired." The new goal for implementation is 2030, and Lockwood said she is pushing to make sure that is the end of the delays. "We have been waiting now for four years," Lockwood said. "That's 40,000 lives we could have saved." CBS News Chicago reached out to several lawmakers trying to repeal the HALT Act for comment for this story, but had not heard back late Monday. Lockwood will be back in Washington, D.C., this September, pushing for the requirement finally to be implemented.

Cassidy: Fentanyl bill 'one more tool for law enforcement'
Cassidy: Fentanyl bill 'one more tool for law enforcement'

American Press

time23-07-2025

  • American Press

Cassidy: Fentanyl bill 'one more tool for law enforcement'

U.S. Sen, Bill Cassidy, M.D. (R-LA), is chair of the Senate Health, Education, Labor, and Pensions (HELP) Committee. (Special to the American Press) Legislation spearheaded by U.S. Sen. Cassidy was signed by President Donald Trump last week. The Halt All Lethal Trafficking (HALT) Fentanyl Act solidifies the classification of fentanyl-related substances as Schedule 1 of the Controlled Substances Act, which is the category for drugs, substances or chemicals with no currently accepted medical use and a high potential for abuse. Fentanyl is a synthetic opioid that is 50 times stronger than heroin and 100 times stronger than morphine, according to the Center for Disease Control and Prevention. Drug overdoses in the United States are predominantly fentanyl-related, contributing to nearly 70 percent of overdose deaths. Fentanyl will be listed at a Schedule 1 drug alongside substances like LSD and cannabis. HALT, which was passed by the U.S. Senate in March, is just 'one more tool for law enforcement to help prevent fentanyl,' Cassidy said during a press briefing on Tuesday. A ceremony for the executive signing of the act was help on Wednesday, July 16. 'During the ceremony, President Trump thanked me, said that this bill is one of the most important things that he will sign this year,' Cassidy said. 'I will agree. One life lost to drug overdoses is too many lives, and we may have as many as 50,000 to 60,000 to 70,000 lives lost annually from fentanyl overdose.' Cassidy thanked Trump in return for addressing the fentanyl epidemic. 'He has worked hard by securing the border, going out to cartels and asking the Chinese to not ship fentanyl precursors to decrease the epidemic. U.S. Customs and Border Protection (CBP) seized 21.9 thousand pounds of fentanyl in 2024. So far this year. As of July 15, CBP has seized 9.2 thousand pounds of fentanyl in 2025. Coca-Cola This week, Coca-Cola announced that the company will expand its product line to include Coca-Cola products made with U.S. Cane Sugar. In the second quarter of 2025 company's report that was released on Tuesday, Coca-Cola said the 'addition is designed to … offer more choices across occasions and preferences.' Cassidy called it a 'great move by President Trump to make America healthier again' that will economically benefit Louisiana through the increased need for sugar. 'Of course, a lot of that sugar is going to come from Louisiana,' he said. 'The cane sugar from Louisiana will be actually healthier than the other type of sugar that they're currently using … and it will obviously give an economic boost to our guys.'

PBI-Gordon Companies, Inc. Calls on Petspan to Cease and Desist False and Misleading Advertisement, Promotion and Sale of Compounded Rapamycin (Sirolimus) for HCM in Cats
PBI-Gordon Companies, Inc. Calls on Petspan to Cease and Desist False and Misleading Advertisement, Promotion and Sale of Compounded Rapamycin (Sirolimus) for HCM in Cats

Business Wire

time21-07-2025

  • Business Wire

PBI-Gordon Companies, Inc. Calls on Petspan to Cease and Desist False and Misleading Advertisement, Promotion and Sale of Compounded Rapamycin (Sirolimus) for HCM in Cats

SHAWNEE, Kan.--(BUSINESS WIRE)--PBI-Gordon Companies, Inc. the parent company of TriviumVet, which holds sole conditional new animal drug approval from the FDA for Felycin ® -CA1 (sirolimus delayed-release tablets) under its affiliated brand company Pegasus, through its outside counsel issued a cease-and-desist demand letter to Petspan for falsely promoting a compounded version of rapamycin (synonymous with sirolimus) for the treatment and management of clinical hypertrophic cardiomyopathy (HCM) in cats. Petspan's evaluation and prescribing practices do not comply with established veterinary practice principles and places the health and wellbeing of cats in jeopardy. Felycin-CA1 is the first and only drug to receive FDA conditional approval for management of ventricular hypertrophy with subclinical HCM in cats. It is also the only conditionally approved drug for which treatment claims are permitted based on studies that were conducted by or on behalf of the holder of the cNADA, TriviumVet. This conditional approval was announced in an FDA press release dated March 14, 2025. Pegasus Laboratories, Inc. ('Pegasus'), another wholly owned subsidiary of PBI-Gordon, launched Felycin-CA1 under the PRN Pharmacal brand at the American College of Veterinary Internal Medicine Forum held June 17-20, 2025, where veterinarians and other participants in attendance were made aware of the availability of Felycin-CA1 through standard distribution channels. PBI-Gordon asserts Petspan is engaging in a pervasive pattern of intentionally false and misleading communications aimed at both veterinarians and pet owners, including claiming product legitimacy from two clinical trials (RAPACAT and HALT-HCM trials) sponsored and conducted by TriviumVet, not Petspan. TriviumVet is currently conducting the HALT-HCM study which is necessary to produce the data required to advance Felycin-CA1 from a conditionally approved drug to a fully approved drug. Petspan's false and misleading public assertions imply that the safety and efficacy of TriviumVet's Felycin-CA1 are applicable to the Petspan compounded product. 'Petspan is illegally marketing an unapproved, unlicensed and potentially unsafe would-be copy of our product, and that has to be stopped,' said PBI-Gordon Companies, Inc. President & CEO Steve Clifford, 'We will take action to stop those who threaten patient safety and urgently call on regulators and law enforcement to do the same.' PBI-Gordon intends to pursue all necessary actions and legal remedies to ensure its product and intellectual property are protected against the false and misleading advertisement and sale of all unapproved versions of sirolimus for HCM, online or otherwise. Feline HCM is extremely common, affecting 1 in 7 of all pet cats. In animals 9 years of age and older, the prevalence rises to approximately 1 in 3 and is a leading cause of mortality in adult cats. The disease is characterized by abnormal thickening and impaired function of the ventricular wall of the heart. While some cats remain asymptomatic, around half go on to develop congestive heart failure or other severe complications. Subclinical HCM refers to cases that have ventricular wall thickening but have not yet developed clinical signs. 'Petspan's unlawful sale of its compounded drug – called Rapamycin – and its false and misleading promotion, poses a real danger to thousands of cats with this condition, and is a callous affront to their owners and veterinarians,' said Dr. Heather Davis DVM, PhD, DACVS-LA, Director of Clinical Affairs and Veterinary Services, Pegasus Laboratories, Inc. PBI-Gordon is also aware that Petspan advertises the diagnosis of HCM and prescription of its compounded 'rapamycin' through telemedicine visits with purported veterinarians. Current gold standard as established by veterinary boards, is to diagnose HCM in-person which involves a veterinarian physically performing a thorough evaluation to rule out other medical conditions that may present as HCM; clinical pathology sampling at a minimum is required in addition to physical examination to make such an assessment. Virtual telemedicine visits are insufficient to establish the relationship, diagnosis, and treatment protocol implementation for HCM in cats. A virtual treatment protocol that misdiagnoses HCM risks negative adverse events to the pet and harm to the future utility of Felycin-CA1 for HCM. More specifically, the letter demands that Petspan immediately cease and desist the following activities: Advertising compounded rapamycin (sirolimus) for the treatment of HCM in cats Relying on studies conducted by or on behalf of TriviumVet as the basis for the Petspan treatment protocol Posting misleading promotional and advertising materials on Petspan's website and social media, including references to studies conducted by or on behalf of TriviumVet Confusing the public by using a synonym for the drug (sirolimus) for which FDA approved the cNADA (i.e., 'rapamycin') About PBI-Gordon Companies PBI-Gordon Companies has been in business in the Kansas City metro area since 1947 and is 100 percent employee-owned. It is the parent company to four subsidiaries which develop, manufacture, and market leading products for Turf and Ornamental Industries (PBI-Gordon Corporation), Companion Animal Pharmaceuticals (Pegasus Laboratories & TriviumVet), and Companion Animal Nutritional Supplements and Grooming Supplies (PetAg). About Pegasus Laboratories Founded in 1986, Pegasus Laboratories is a pharmaceutical development and manufacturing organization focused on novel products to treat chronic conditions in cats, dogs, and horses. Pegasus provides full-service Contract Development and Manufacturing Organization (CDMO) focusing on the development and manufacturing with full turn-key technical services in a DEA-approved CGMP facility. Pegasus also provides a full portfolio of pharmaceuticals, nutritional therapeutics and supplements, parasite control and surgical and wound care under the PRN® and Sē·Qual™ brands. About TriviumVet TriviumVet is an Ireland-based research and development company. Working with some of the leading veterinarians and therapeutic specialists around the world to address the gaps in disease management by developing innovative new therapeutic solutions for some of the most serious and underserved conditions. Focused on finding effective treatments for unmet needs in cardiology, renal health, pain management, gastroenterology, wellness testing, and age-related diseases.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store